Cargando…
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout
BACKGROUND: Dotinurad is a novel selective urate reabsorption inhibitor (SURI) which reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1). This study was intended to verify the efficacy and safety of dotinurad following treatment for 34 or 58 weeks in hyperuricemic pa...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066281/ https://www.ncbi.nlm.nih.gov/pubmed/31875931 http://dx.doi.org/10.1007/s10157-019-01831-5 |